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Abstract
Cirrhosis is an increasing cause of morbidity and mortality in more developed coun-
tries, being the 14th most common cause of death worldwide. Hepatocellular carcinoma 
(HCC) consists a significant health issue worldwide, responsible for more than 1 mil-
lion deaths annually. The incidence and mortality rates vary across different geographi-
cal areas. Between 60 and 90% of HCC patients already have liver cirrhosis, attributed 
mainly to chronic hepatitis B and C, alcohol abuse, and non-alcoholic fatty liver disease 
(NASH). The surgical management of HCC in the setting of liver cirrhosis with curative 
intent includes liver resection, ablation or microwave coagulation, and liver transplanta-
tion (LT). Liver resection in a cirrhotic liver with HCC is associated with lower survival 
rates compared with liver transplantation (LT), depending on the diseases’ stage but on 
the contrary liver resection could be potentially offered in a larger population compared 
to liver transplantation. One of the biggest limitations of liver resection is the risk of 
tumor recurrence, which is high, and it may exceed 70% 5 years after the procedure. Liver 
transplantation is considered the best treatment for hepatocellular carcinoma at early 
stages because it removes the tumor as well as the underlying cirrhotic liver.
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1. Introduction
Cirrhosis is an increasing cause of morbidity and mortality in more developed countries, 
being the 14th most common cause of death worldwide. The natural history of cirrhosis 
is initially compensated and is asymptomatic progressing into decompensated cirrhosis 
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with portal hypertension and liver dysfunction and in the development of hepatocellular 
carcinoma (HCC).
Hepatocellular carcinoma consists a significant health issue worldwide, responsible for more 
than 1 million deaths annually. The incidence and mortality rates vary across different geo-
graphical areas [1, 2]. Between 60 and 90% of HCC patients already have liver cirrhosis, attrib-
uted mainly to chronic hepatitis B and C, alcohol abuse, and non-alcoholic fatty liver disease 
(NASH). In the past, HCC was usually diagnosed late during the course of the liver disease, 
and consequently, the vast majority of patients had a poor prognosis at diagnosis. Survival 
is poor, and high recurrence rates after treatment were exhibited regardless of treatment. 
Currently, the implementation of screening programs especially for chronic virus hepatitis, 
and advances in radiological assessment, leads to an increasing proportion of patients being 
diagnosed within early stage of HCC. The surgical management of HCC in the setting of liver 
cirrhosis with curative intent includes liver resection, ablation or microwave coagulation, and 
liver transplantation (LT).
2. Hepatocellular carcinoma staging
Cancer staging should serve to select the appropriate primary and adjuvant therapy, to esti-
mate the prognosis, and also to assist in the evaluation of the results of treatment and this is 
also applicable in HCC [3, 4]. The EASL panel of experts recommended the consideration of 
four-related aspects: tumor stage, degree of liver function impairment, general condition of 
the patient, and treatment efficacy [5]. In the past, the Okuda classification [6] has been widely 
applied in HCC patients, and it included parameters related to the liver functional status like 
albumin, ascites, and bilirubin. The Cancer of the Liver Italian Program (CLIP) score [7] was 
proposed and validated [8]. It combines four variables that provide a seven-stage classifica-
tion system and was more discriminatory compared with Okuda stage and TNM. Groups 
from Asia published different survival rates compromising its external validation [9]. The 
Barcelona-Clinic Liver Cancer (BCLC) staging system [10] was proposed by the Barcelona 
group on the basis of the results obtained from cohort and RCT studies. It consists a staging 
classification that uses variables related to performance status, tumor stage, liver functional 
status, characteristic of the tumor, vascular invasion, and the presence of portal hyperten-
sion (PH). This BCLC classification system has become a widely accepted algorithm for all 
HCC patients in earlier disease, linking their current status prognosis with treatment recom-
mendations. Recently, a new staging system was proposed from the Hong Kong group [11]. 
The Hong Kong Liver Cancer (HKLC) used four prognostic factors in the treatment of HCC, 
the Eastern Cooperative Oncology Group performance status (ECOG PS), Child-Pugh grade, 
liver tumor status, and presence of extrahepatic vascular invasion/metastasis. Liver tumor 
status was a composite factor of the size of the largest tumor in the liver, number of tumor 
nodules, and the presence or absence of intrahepatic vascular invasion. The authors support 
that the HKLC staging classification has the potential to provide better prognostic classifica-
tion than BCLC staging and may be more effective in identifying patients suitable for more 
aggressive treatments, hence yielding a better survival outcome.
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3. Liver resection vs. TACE and RFA
Liver resection when it is feasible, in a cirrhotic liver with HCC, is associated with lower 
survival rates compared with liver transplantation (LT), varying from 35 to 62% at 3 years 
and from 17 to 50% at 5 years, depending on the diseases’ stage but on the contrary liver 
resection could be potentially offered in a larger population compared to liver transplanta-
tion. One of the biggest limitations of liver resection is the risk of tumor recurrence, which 
is high, and it may exceed 70% 5 years after the procedure. Hepatic resection tends to be 
applicable only in patients with cirrhosis that is classified as Child-Pugh class A or B and 
with mild portal hypertension. The application of palliative therapies like radiofrequency 
ablation (RFA), microwave coagulation (MC) and transarterial chemoembolization (TACE) is 
frequently limited by impaired hepatocellular function, severe portal hypertension, or mul-
tiple tumor nodules.
Huang et al. [12] in a large randomized trial of 230 patients within the Milan criteria (BCLC 
stage A) compared surgical resection and radiofrequency ablation for HCC patients indicat-
ing a favorable outcome for surgically treated patients. Wang et al. in their meta-analysis 
evaluated three randomized and 25 nonrandomized trials, and they confirmed the long-
term superiority of surgical treatment [13]. In another meta-analysis by Kapitanov et al. and 
taking into account the limited available literature and prospective studies, they concluded 
that liver resection shows significantly improved long-term survival compared to TACE in 
cirrhotic patients with BCLC stage A and B HCC. T. Utsunomiya et al. conducted a large 
prospective multicenter trial and demonstrated clear superiority for hepatic resection when 
compared to TACE and RFA for patients with Child-Pugh stage A and B liver cirrhosis and 
stage II HCC (JIS scores 1 and 2) [14]. Peng et al. [15] showed that even for patients with por-
tal venous tumor, thrombus liver resection improves long-term survival compared to TACE 
as long as tumor thrombosis was confined to the liver. This effect vanished in the presence of 
extensive tumor thrombosis into the portal venous confluence and the superior mesenteric 
vein. Zhong et al. [16] demonstrate clear superiority for hepatic resection versus TACE in 
terms of patient survival. They analyzed an impressive total number of 1259 of patients with 
the vast majority of cases being hepatitis-B positive. Limitations of the study were a rather 
heterogeneous patient collective and a mean patient age and tumor size being both greater in 
the TACE group. For this reason, matched-pair analysis was performed between TACE and 
resection patients with identical demographics confirming the positive overall results for 
surgically treated patients.
Laparoscopic liver resection (LLR) consists a contemporary surgical approach in the manage-
ment of hepatocellular carcinoma with or without liver cirrhosis. The indications for LLR 
have changed substantially since its introduction. In the beginning, it was limited to benign 
diseases, while gaining increased knowledge and experience of the procedure, its indications 
have expanded to malignant diseases, including HCC and colorectal liver metastasis [17]. 
However, laparoscopy has been limitedly used for liver resection due to the risk of air embo-
lism and the difficulty of parenchymal dissection and bleeding control [18]. Therefore, LLR 
has been frequently performed for tumors superficially located in the anterolateral segments 
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[19]. Liver cirrhosis consists a substantial risk factor for developing postoperative complica-
tions following hepatectomy. Severe blood loss or prolonged ascites after major hepatectomy, 
especially by open surgery, can occur by interruption of collateral circulation in the parietal 
wall and surrounding ligamentsin patients with liver cirrhosis [20] and may prolong the post-
operative hospital stay or induce hepatic failure in some patients. However, LLR may mini-
mize the reduction in collateral and lymphatic flow caused by laparotomy and mobilization 
[21, 22]. The benefits of LLR in liver cirrhosis include enhanced recovery, less postoperative 
pain, and potentially less postoperative complications. Other important advantages of LLR in 
patients with liver cirrhosis are the lower incidences of postoperative liver failure and ascites 
due to minimal invasiveness of LLR, which helps to preserve collateral circulation. Therefore, 
laparoscopic hepatectomy may be a good option in patients with cirrhosis [23].
4. Down-staging and bridge therapies
4.1. TACE
Down-staging in HCC patients includes but not limited to TACE, radiofrequency ablation 
(RFA), percutaneous ethanol injection (PEI), microwave coagulation (MC), resection, and radi-
ation [24]. The objective of down-staging is to decrease the tumor size and/or number of nod-
ules in those patients that initially are presenting with tumors beyond the acceptable criteria 
for liver transplantation in different centers. The response to different DS treatment has to be 
based on radiological measurement of tumor characteristics. The EASL HCC guidelines sug-
gested, and this was also endorsed by the AASLD guideline, that assessment of tumor response 
should consider only the area of viable tumor [25], defined by arterial enhancement on a radio-
logical contrast study modified response evaluation criteria in solid tumors (mRECIST).
Prospective studies showed that survival after liver transplantation in patients with large 
tumor burden successfully treated by down-staging was similar to survival in patients who 
initially met the criteria for transplantation [26]. There is currently no well-defined upper limit 
for size and number of lesions as eligibility criteria for down-staging, although the presence of 
vascular invasion and extrahepatic disease is generally considered absolute contraindications.
The role of DS has been ambiguous concerning the overall and recurrence-free survival 
post-transplantation. In the case that complete tumor necrosis with locoregional therapy is 
achieved, this is associated with better survival. A multicenter case-control study compared 
matched patients with TACE (100) and without TACE (100) [27] showed that survival rates 5 
years after OLT were similar 59.3% versus 59.4%, respectively. In addition, there were fewer 
recurrences in the TACE group although this was not statistically significant. Moreover, the 
waiting times were short, and the median number of TACE procedures was only 1, and this 
may impact negatively the detection of any advantage for TACE.
Comparisons of the dropout rates of treated and untreated patients are limited with the exist-
ing data. Yao et al. from the UCSF analyzed 70 patients a proportion of them having pretrans-
plant therapy either TACE or ablation, and this was associated with a significantly lower risk 
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of dropout. Disadvantage of the study was that the population was heterogeneous regard-
ing the disease stage, and the criteria for treatment were influenced by external factors [28]. 
Another study from Toronto including 74 patients identified a difference in tumor-related 
dropout that became apparent only after 300 days [29].
Drug-eluting beads loaded with chemotherapy agents are delivered into the tumor through 
the feeding artery. Chemotherapy agents are released gradually, so systemic side effects are 
reduced, and tumor drug delivery is enhanced. The PRECISION study compared conven-
tional TACE with DEB for the treatment of 212 patients with Child-Pugh A or B cirrhosis 
and unresectable HCC [30]. Subpopulation analysis revealed that patients with Child-Pugh 
B cirrhosis or bilobar tumor disease showed a better response to DEB. In addition, the overall 
DEB was better tolerated than conventional TACE. While it appears that DEB might be better 
tolerated than conventional TACE, more extensive data are needed.
4.2. RFA
The use of RFA as a bridge to transplantation in HCC patients is also applicable. It has been 
reported complete tumor necrosis at pathological evaluation of the explanted liver in 47–75% 
of cases, with a mean value of 58% [31–35]. Different rates of complete necrosis ranges have 
been observed between 50 and 78% in HCCs up to 3 cm and between 13 and 43% in larger 
neoplasms, respectively [31–33]. Furthermore, in two studies, a tumor size larger than 3 cm 
was the only risk factor found for HCC recurrence after treatment [31–33]. Analysis of the 
largest available series of HCC patients awaiting LT regarding RFA-related complications 
showed the safety of the procedure. From five large series, we could see that the mean rate of 
post-ablation major complications was below 5% [31–36], and in addition, the risk of tumor 
seeding at the level of the abdomen wall appears to be low.
4.3. Liver resection
Belghiti [37] proposed that resection can be used as an alternative treatment option for HCC 
or before LT as “down-staging” procedure. Liver resection can be used as a primary therapy 
in patients with HCC and well-preserved liver function, with LT reserved as a “salvage” ther-
apy for patients who developed recurrence or liver failure. Moreover, resection can be used 
as an initial therapy in order to select patients whose explants pathology would be favorable 
for LT. Resection could also be used as a “bridge” therapy for patients who have been already 
enlisted for LT. Whether resection or LT should be the treatment of choice for small HCC in 
patients with preserved liver function is a hot issue and still in debate. Long-term overall 
survival after resection or transplantation appears comparable in a well-selected population 
with HCC within the Milano criteria [37–39]. LT has the advantage of increased disease-free 
survival compared with liver resection, but its use is limited by shortage of liver organs. It has 
been proposed by the group of Belgiti but also from other groups that resection as the first-
line treatment for patients with small HCC with preserved liver function, followed by salvage 
transplantation only for recurrence or liver failure, would feasible in a large proportion of 
HCC patients [37–39].
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Considering emergency LT after resection as center, policy would require a strict selection of 
the candidate with clear and strong indicators of irreversible postoperative liver insufficiency. 
Patients with liver failure due to massive necrosis of the remnant liver or those with uncon-
trollable bleeding are easy to be identified, but it is unclear and very difficult to ascertain 
the irreversibility of liver insufficiency in all settings. A significant increase in international 
normalized ratio (INR) and serum bilirubin within the first postoperative days is a common 
characteristic of extended resection making identification and selection of patients in need for 
early liver transplantation tricky. It is documented that, in the absence of any treatable com-
plication, the lack of significant improvement on postoperative day 5 may lead to strongly 
considering rescue transplantation [40].
Poon et al. [38] proposed liver resection for HCC lesions in selected patients eligible for LT 
and to reserve LT for those who develop recurrence or deterioration of liver function. This 
approach, which proposes resection as a bridge treatment to prevent tumor progression dur-
ing the waiting period, looks attractive but has not been studied well, especially with pro-
spective studies and needs external validation of published data from the various transplant 
centers. As major concern from transplant surgeons is that prior liver resection especially if 
done in no-specialized centers could complicate the operative transplant procedure, increase 
the risk of postoperative complications, and finally compromise results and impair the sur-
vival advantage of transplantation over resection alone.
5. Liver transplantation
Liver transplantation is considered the best treatment for hepatocellular carcinoma at early 
stages because it removes the tumor as well as the underlying cirrhotic liver. However, as a 
result of organ shortage, it is anticipated that transplantation to HCC patients will be per-
formed with an expected five-year post-transplantation survival of greater than 50%, and, 
in most programs, an expected five-year post-transplantation survival similar to survival 
achieved after liver transplantation for benign liver diseases (i.e., 70%).
In 1996, Mazzaferro et al. [41] conducted a prospective cohort study defining restrictive selec-
tion criteria (Milan Criteria (MC)) that led to improved survival for transplant patients com-
pared with any other previous experience with transplantation for HCC. Adopting the MC 
demonstrated a five-year survival of 70% after LT [41]. The survival outcome of MC is compa-
rable to LT in benign diseases and given that this excellent outcome MC has been established 
from most liver societies (EASL and AASLD guidelines) as the golden standard in selecting 
HCC patients for liver transplant [42, 43].
In 2001, Yao et al. from University of California San Francisco (UCSF) [44] demonstrated a 
tumor recurrence rate of little more than 10% and survival rates exceeding 70% in T1, T2 and 
T3 tumors. The new criteria included solitary tumors smaller or equal to 6.5 cm in size or three 
or fewer tumors with the largest diameter not exceeding 4.5 cm and the total tumor diameter 
being less or equal to 8 cm and became known as the UCSF criteria.
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Alternative criteria have been proposed by other centers. These include criteria from the Asan 
Medical Center in Korea [45], from Hangzhou, China [46], the University Clinic of Navarra 
in Spain [47], Kyoto, Japan [48]. All use different criteria in terms of number of nodules and 
size and in addition try to implement some biological criteria like α-FP, protein induced by 
vitamin K absence II (PIVKA II) and other. Unfortunately, none of these criteria have been 
externally validated in order to get wider acceptance.
In 2009, the Metroticket was introduced by Mazzafero et al. [49]. The Metroticket introduced 
the logic that the further you expand HCC staging criteria for LT, this would impact nega-
tively the outcome in terms of higher recurrence rates and poorer overall survival. This model 
potential could be a simple predictive model for estimating the survival of patients undergo-
ing LT with tumors exciding the Milan criteria in number and size of the tumors.
High α-fetoprotein (AFP) levels are predictive of poor prognosis in non-transplant patients, 
and AFP levels greater than 1000 ng/mL have been associated with a high risk of recurrence in 
the University of California, San Francisco (UCSF), experience [44] after liver transplantation.
AFP value is proposed as a good indicator in selecting HCC patients for LT [50, 51]. In the 
non-transplant patients, an elevated AFP is a marker of advanced disease. It has been pro-
posed that an increase in AFP levels might be an indicator of tumor aggressiveness including 
differentiation degree and vascular invasion and, consequently, lead to a higher risk of tumor 
recurrence. Toso et al. [52] analyzed adult recipients in the Scientific Registry of Transplant 
Recipients. In the multivariate analysis, it was shown that high AFP levels and TTV >115 cm3 
were associated with poor long-term survival.
Duvoux et al. [53] in a French multicenter study showed that AFP levels strongly correlated 
with the pathologic features of HCC. Based on the analysis of 453 explanted livers, they found 
that increased AFP levels were associated with vascular invasion and loss of differentiation.
Living Donor Liver Transplantation (LDLT) consists of an alternative option to Deceased Donor 
Liver Transplantation (DDLT). Special consideration regarding LDLT for HCC is required, 
since patients for LDLT are not dependent of the cadaveric donor pool, but bring their “own” 
liver graft. It is important to stress that the application of strict eligibility criteria similar the 
one required with cadaveric grafts for patients with HCC might not be necessary. However, 
survival benefit to the recipient should be substantial, and the risk to the donor must be incor-
porated into the centers policy, since it is clearly unethical to expose a donor to a significant 
risk of morbidity or mortality. Generally, similar criteria apply to patients undergoing DDLT 
or LDLT. For patients subjected to either DDLT or LDLT for HCC within MC, similar outcomes 
have been documented [54, 55]. Asian groups have proposed different policies concerning dif-
ferent criteria for LDLT in the setting of HCC. The Tokyo group applies the 5–5 rule (number of 
tumors not exceeding 5 and maximum tumor diameter not exceeding 5 cm); the Kyoto group 
the 10–5 rule (number of tumors not exceeding 10; each tumor not exceeding 5 cm) in combi-
nation with the biological tumor marker PIVKA (or DCP) (not exceeding 400 mAu/ml), and 
finally, the Seoul group adopts an intermediate policy with limiting the number of tumors not 
exceeding 6 and the maximum tumor diameter not exceeding 5 cm. All three groups obtained 
around 85% 3–5 years disease free survival (DFS) survival rates.
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In the West, LDLT is often stretched in patients who do not strictly meet the Milan criteria 
for MELD exception points and have tumors with a probable worse prognosis. Updated re-
analyzed data of the A2ALL cohorts concluded that “differences in tumor characteristics and 
management of HCC in patients who received LDLT likely accounted for the higher HCC 
recurrence rates observed in their LDLT group.”
Systematic review analysis by Grant et al. [56] suggests that DFS is worse after LDLT com-
pared with DDLT for HCC. Decreased DFS may eventually translate to decreased OS, and 
it is advisable that the increased risk of recurrence should be communicated to all potential 
donors and recipients who are considering LDLT for HCC.
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